title: Bazedoxifene: a guide to its use in postmenopausal osteoporosis.
abstract: Oral bazedoxifene (Conbriza®) reduces the incidence of new vertebral fractures in patients with postmenopausal osteoporosis. It also appears to reduce the risk of nonvertebral fractures in high-risk patients. Bazedoxifene is generally well tolerated and does not appear to have detrimental effects on endometrial or breast tissue.
authors.affiliation: Adis, Auckland, New Zealand.
authors.forename: Gillian M
authors.initials: GM
authors.lastname: Keating
authors.forename: Katherine A
authors.initials: KA
authors.lastname: Lyseng-Williamson
authors.forename: Sean T
authors.initials: ST
authors.lastname: Duggan
authors.forename: Kate
authors.initials: K
authors.lastname: McKeage
mesh_terms: D005260:Female; D050723:Fractures, Bone / Q000150:complications / Q000188:drug therapy; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy*
chemical_list: D007211:Indoles; C447119:bazedoxifene